Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Small Cell Lung Carcinoma 2Sarcoma 2Melanoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Skin Neoplasms 1Resectable Hepatocellular Carcinoma 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Ichthyosis, X-Linked 1Glioma 1

Interventions

Sorafenib 131lenvatinib 115Bevacizumab 88Radiosurgery 69atezolizumab 55sintilimab 54Nivolumab 51durvalumab 43Hepatectomy 43Fluorouracil 42apatinib 41Oxaliplatin 41camrelizumab 38Radiofrequency Ablation 38pembrolizumab 36Radiotherapy 36tislelizumab 35Leucovorin 31Magnetic Resonance Spectroscopy 30Immune Checkpoint Inhibitors 28Doxorubicin 28Folfox protocol 26tremelimumab 25regorafenib 25Cisplatin 20spartalizumab 19donafenib 19Gemcitabine 19Cyclophosphamide 19toripalimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Hepatocellular × ADI PEG20 × Clear all
NCT06006286 2024-08-26

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT06034977 2023-09-13

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Chang Gung Memorial Hospital

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡